UNLOCKING THE FULL VALUE OF MEDICAL IMAGES

Canaccord Drug and Device Conference, Noosa
October 2025

ASX:SHG

Disclaimer

This presentation ("Presentation") has been prepared by Singular Health Group Ltd ("Singular Health" or "Company"). You must read and accept the conditions in this notice before considering the information set out in, or referred to, in this Presentation. If you do not agree, accept, or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Singular Health. By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Singular Health from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation.

No Offer

This Presentation is not a prospectus, product disclosure statement, or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC). This Presentation does not constitute investment or financial product advice (nor tax, accounting, or legal advice) or any recommendation to acquire shares of Singular Health and will not form any part of any contract for the acquisition of shares of Singular Health.

Summary Information

This Presentation contains summary information about Singular Health, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete, nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Singular, or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. While Singular Health has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation.

Not Investment Advice

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainties and contingencies which may affect future operations of Singular Health and the impact that different future outcomes may have on Singular Health. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs, and seek legal, accounting and taxation advice appropriate to their jurisdiction. Singular Health is not licensed to provide financial product advice in respect of Singular Health shares. Cooling off rights do not apply to the acquisition of Singular Health shares.

Investment Risk

An investment in Singular Health shares is subject to known and unknown risks, some of which are beyond the control of Singular Health. Singular Health does not guarantee any particular rate of return or the performance of Singular Health nor does it guarantee any particular tax treatment. An investment in Singular Health should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business.

Financial Data

All dollar values in this Presentation are in Australian dollars (A$ or AUD) unless otherwise stated.

Forward-looking Statements

This Presentation may contain forward looking statements. The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan', and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in this statements are reasonable, but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You should not place undue reliance on forward-looking statements and neither Singular Health nor any of its directors, employees, advisers or agents assume any obligation to update such information.

Disclaimer

None of Singular Health's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted, or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them. To the maximum extent permitted by law, Singular Health and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Singular Health and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, Singular Health and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice.

This presentation has been authorized for released by the Board of Singular Health.

COMPANY SNAPSHOT

Share Price	$0.275
Shares on Issue	312.6 Million
Market Capitalisation	$85.9Million
Cash at Bank (30 June)	$13.7 Million
Enterprise Value	$72.3 Million
Top 50 Shareholders	61.57%



We are developing a fully integrated healthcare ecosystem that enables interoperability and unlocks the full value of medical imaging records to empower patients and practitioners to make more-informed decisions.

LACK OF IMAGING INTEROPERABILITY



3DICOM-ENABLED INTEROPERABILITY



SHG's MFTP enables the transfer of medical imaging records (PACS agnostic) between healthcare systems

- Fully encrypted system to ensure data integrity
- Preventing redundant imaging
- Reducing patient discomfort
- Supporting timely medical intervention and;
- Lowering costs

WITH 3DICOM SOLUTION



3DICOM's ENABLED AGGREGATION & SHARING OF MEDICAL IMAGING RECORDS

- Fewer unnecessary scans
- Faster diagnoses
- Improved patient satisfaction
- Reduced cancellation of specialists' appointments

WHO IS PROVIDER NETWORK SOLUTIONS (PNS)

PNS is a healthcare management company specializing in Specialty Managed Service Organization (MSO) and Third-Party Administrative services. Founded in 1998, PNS collaborates with health plans, primary care providers, and specialists to enhance patient care and optimize healthcare delivery. PNS now manages the health care of more than 3.7-million-member plans across Florida, Texas and Puerto Rico.

In August 2023, PNS established a JV with Healthcare Outcomes Performance Company (HOPCo), a healthcare management company, further expanding its capabilities and reach.

As of October 2023, HOPCo manages healthcare facilities and partnerships in more than 30 U.S. states with a focus on value-based care. [5]
(Becker's Spine)



5. https://www.beckersspine.com/orthopedic/58112-hopco-grows-to-a-1b-venture.html

Commercial Contract Signed with PNS

USD $1.3m contract signed with PNS to be deployed and implemented across PNS's PCP network

Purchase of 1,000 3DICOM MD licences at USD$800 per licence (licences to be renewed annually)

- $500,000 one-off payment for development cost associated with the AI model and centralised imaged repository



Co-designed Pilot Contract to specifically address:

- ✓ **Unnecessary duplicate imaging**
- ✓ **Delays in disease detection**
- ✓ **Lack of centralised access to medical imaging**

Initial deployment to 1000 PCPs across the PNS network in Puerto Rico, Florida and Texas

Successful pilot to position SHG for its first, large-scale, national rollout via the PNS joint venture network with other MSOs, Healthcare Organisations and Health Plans

Investment Highlights

Proven technology technical Proof of Concept completed for 3DICOM™ software with strategic MSO partner, Provider Network Solutions (PNS)

Commercial Contract signed with PNS USD$1.3m commercial contract executed with PNS for the initial rollout of 1,000 3DICOM™ licences to PNS

Total Addressable Market opportunity for SHG in the US of $19bn Commissioned independent research from Signify Research that highlights the size of the revenue opportunity for SHG

Engagement commenced with other MSO's and Healthcare plans for the national rollout in the United States of SHG's 3DICOM™ solution

Strong balance sheet with $13m cash- Fully funded for national rollout and product development

FOR MORE INFORMATION PLEASE CONTACT:

Denning Chong
Managing Director & CEO
Singular Health Group
denning@singular.health
1300 167 795

Paul Berson
Investor Relations
Corporate Storytime
paul@corporatestorytime.com
0421 647 445